DIESSE announces a strategic partnership with Grifols to develop and commercialize tests for biologic drugs monitoring

Siena, June 23 2021 – DIESSE Diagnostica Senese has signed a strategic agreement with Grifols for the development and commercialization of Grifols’ Promonitor tests on DIESSE’s Chorus analyzer.

Grifols, a leader in biological drug monitoring with its Promonitor test platform, offers a comprehensive test panel that can provide key information on drug bioavailability and immunogenicity in patients receiving biological therapy for the treatment of chronic inflammatory diseases and other indications.

Biologic drugs monitoring, along with clinical findings, ensures personalized treatment for each patient, contributing to valuable information that enables a customized approach. In addition, early information about potential reduced drug efficacy provides an early warning about the fact that the treatment regime may require modification.

DIESSE immunoassay analyzer Chorus TRIO with ready-to-use devices and a menu of more than 150 available tests is the ideal, reliable and simple solution for the assay of immunodiagnostic specialties without any waste of material thanks to its single test devices, made today even more flexible and effective in providing diagnostic information in a short time and with DIESSE quality.

The development of Promonitor tests on the Chorus automated system across Europe will improve the efficiency and ease of use while maintaining the high quality of results and improving overall patient management.

“We are very proud that Grifols has chosen us to include its Promonitor solution to monitor biologic drugs,” states Luigi Nava, Commercial Operations Director of DIESSE . “New Promonitor tests for Chorus represent another milestone aligned with DIESSE’s strategy called Diagnostics Evolution, pursuing the objective of offering continuous innovation and improving people’s lives.”

“Grifols is pleased to partner with DIESSE to provide its state-of-the art Promonitor family of tests to measure both drug levels and anti-drug antibody levels to improve the care of patients and their well-being,” says Guillermo Marco-Gardoqui, vice president, Global Clinical Diagnostics, Grifols.

This agreement confirms the importance of combining complementary knowledge in the world of Diagnostics. It will accelerate innovation and guarantee the consistency of solutions offered to diagnostic laboratories.